AB2 Bio will receive $30 million from Nippon Shinyaku after [...]
FDA recognition accelerates development of first-in-class mitochondrial cell therapy for [...]
AB2 Bio will receive $30 million from Nippon Shinyaku after [...]
FDA recognition accelerates development of first-in-class mitochondrial cell therapy for [...]